Gut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol.

TitreGut microbiota, short chain fatty acids, and obesity across the epidemiologic transition: the METS-Microbiome study protocol.
Publication TypeJournal Article
Year of Publication2018
AuthorsDugas, LR, Lie, L, Plange-Rhule, J, Bedu-Addo, K, Bovet, P, Lambert, EV, Forrester, TE, Luke, A, Gilbert, JA, Layden, BT
JournalBMC public health
Volume18
Issue1
Pagination978
Date Published08/2018
DOI10.1186/s12889-018-5879-6
ISSN1471-2458
Mots-clésepidemiologic transition, Gut microbiota, Obesity, Short chain fatty acids
Abstract

BACKGROUND: While some of the variance observed in adiposity and weight change within populations can be accounted for by traditional risk factors, a new factor, the gut microbiota, has recently been associated with obesity. However, the causal mechanisms through which the gut microbiota and its metabolites, short chain fatty acids (SCFAs) influence obesity are unknown, as are the individual obesogenic effects of the individual SCFAs (butyrate, acetate and propionate). This study, METS-Microbiome, proposes to examine the influence of novel risk factors, the gut microbiota and SCFAs, on obesity, adiposity and weight change in an international established cohort spanning the epidemiologic transition.

METHODS: The parent study; Modeling the Epidemiologic Transition Study (METS) is a well-established and ongoing prospective cohort study designed to assess the association between body composition, physical activity, and relative weight, weight gain and cardiometabolic disease risk in five diverse population-based samples in 2500 people of African descent. The cohort has been prospectively followed since 2009. Annual measures of obesity risk factors, including body composition, objectively measured physical activity and dietary intake, components which vary across the spectrum of social and economic development. In our new study; METS-Microbiome, in addition to continuing yearly measures of obesity risk, we will also measure gut microbiota and stool SCFAs in all contactable participants, and follow participants for a further 3 years, thus providing one of the largest gut microbiota population-based studies to date.

DISCUSSION: This new study capitalizes upon an existing, extensively well described cohort of adults of African-origin, with significant variability as a result of the widespread geographic distributions, and therefore variation in the environmental covariate exposures. The METS-Microbiome study will substantially advance the understanding of the role gut microbiota and SCFAs play in the development of obesity and provide novel obesity therapeutic targets targeting SCFAs producing features of the gut microbiota.

TRIAL REGISTRATION: Registered NCT03378765 Date first posted: December 20, 2017.

Alternate URL

http://www.ncbi.nlm.nih.gov/pubmed/30081857?dopt=Abstract

WOS ID (UT)

000441216400006

Alternate JournalBMC Public Health
Citation Key / SERVAL ID9025
Peer reviewRefereed
PubMed ID30081857
PubMed Central IDPMC6090745
Grant ListR01-DK111848 / / National Institute of Diabetes and Digestive and Kidney Diseases /

                         

IUMSP | www.iumsp.ch
Institut universitaire de médecine sociale et préventive
Route de la Corniche 10, 1010 Lausanne - Switzerland
+41 21 314 72 72 | iumsp@chuv.ch

Go to top